Vancouver, British Columbia--(ACN Newswire via SeaPRwire.com - October 30, 2025) - Doubleview Gold Corp. (TSXV: DBG) (OTCQB: DBLVF) (FSE: 1D4) (the "Company" or "Doubleview") is pleased to announce a non-brokered private placement of flow-through shares and non-flow-through units for gross proceeds of up to C$10,000,000 (the "Private Placement"). Proceeds of the Private Placement shall be used to fund the current exploration program and general working capital. Proceeds of the sale of the FT Shares will be used for exploration work on its BC projects, particularly for the polymetallic Hat Project, located in northwestern BC. This work includes drilling, geological advisory and analytical services as well as other development work and other "Canadian exploration expenses" that qualify as "flow-through mining expenditures" (as such terms are defined in the Income Tax Act (Canada) (the "Tax Act")).The flow-through portion of the Private Placement will consist of up to 5,000,000 flow-through Shares ("FT shares ") at a price of $1.00 per FT share for up to C$5,000,000.Additionally, the Company will issue up to 7,142,857 hard dollar units ("non-FT Units") at a price of $0.70 per non-FT Unit, for up to C$5,000,000. Each non-FT Unit will consist of one common share and one full Warrant at an exercise price of $1.00 for 24 months from the date of issue. Each Warrant shall be subject to an accelerated expiry date at the option of the Company in the event the ten (10) day volume-weighted average price of the common shares of the Company on the TSXV for any ten (10) consecutive trading days is $1.25 or more.Pursuant to applicable Canadian securities laws and in accordance with the TSX Venture Exchange policies, all securities issued under this Offering will be subject to applicable resale restrictions under applicable securities laws and to the Exchange hold period of four-months and one day from the date of issuance. In connection with the Private placement, Doubleview may pay a finder's fees in accordance with the policies of the TSXV consisting of cash and/or finder's shares.The closing of the Offering is subject to receipt of all necessary regulatory approvals including the TSX Venture ExchangeAbout Doubleview Gold CorpA mineral resource exploration and development company is headquartered in Vancouver, British Columbia, Canada. It is publicly traded on the TSX Venture Exchange (TSXV: DBG) (OTCQB: DBLVF) (WKN: A1W038) and (FSE: 1D4). Doubleview focuses on identifying, acquiring, and financing precious and base metal exploration projects across North America, with a strong emphasis on British Columbia. The company enhances shareholder value through the acquisition and exploration of high-quality gold, copper, cobalt, scandium, and silver projects-collectively critical minerals-utilizing cutting-edge exploration techniques.Doubleview's success is deeply rooted in the unwavering support of its long-term shareholders, supporters, and institutional investors. Their ongoing commitment has been instrumental in advancing the company's strategic initiatives. Doubleview looks forward to further collaborative growth and development and continues to welcome active participation from its valued stakeholders as the company expands its portfolio and strengthens its position in the critical minerals sector.About the Hat Polymetallic DepositThe Hat Deposit, located in northwestern British Columbia, is a polymetallic porphyry project with major resources of copper, gold, cobalt, and the potential for scandium. As one of the region's significant sources of critical minerals, the Hat deposit has undergone targeted exploration and development. The 0.2% CuEq cut-off resource estimate, as of the recently completed Mineral Resource Estimate and the Company's July 25, 2024, news release, is summarized below:Open Pit Model HatResource CategoryTonnageAverage GradeMetal ContentCuEqCuCoAuAgCuEqCuCoAuAgMt%%%g/tg/tmillion lbmillion lbmillion lbthousand ozthousand ozIn PitIndicated1500.4080.2210.0080.190.421,353733289292,045Inferred4770.3440.1850.0090.150.493,6191,945912,3287,575 Scandium potential for the Hat Deposit is estimated to be 300 to 500 million tonnes at an average grade of 40 ppm (0.004%) Sc2O3.For further details, please refer to the Company's July 25, 2024 news release.Qualified Person:Erik Ostensoe, P. Geo., a consulting geologist, and Doubleview's Qualified Person with respect to the Hat Project as defined by National Instrument 43-101 Standards of Disclosure for Mineral Projects, has reviewed, and approved the written technical disclosure contained in the news release. He is not independent of Doubleview as he is a shareholder in the company.On behalf of the Board of Directors,Farshad Shirvani, President & Chief Executive OfficerFor further information please contact:Doubleview Gold CorpVancouver, BC Farshad ShirvaniPresident & CEOT: (604) 678-9587E: corporate@doubleview.caNEITHER TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.The information contained herein contains "forward-looking information" and "forward-looking statements" within the meaning of applicable securities legislation (collectively, "forward-looking statements"). Forward-looking statements relate to information that is based on assumptions of management, forecasts of future results, and estimates of amounts not yet determinable. All statements, other than statements of historical fact, are forward-looking statements and are based on predictions, expectations, beliefs, plans, projections, objectives and assumptions made as of the date of this news release, including without limitation: the size of the Private Placement and other statements concerning the Private Placement; the anticipated use of proceeds from the Private Placement; the renunciation to the purchasers of FT Shares and timing thereof; the tax treatment of the FT Shares and the Company's plans regarding exploring its mineral exploration properties; anticipated results of geophysical drilling programs, geological interpretations and potential mineral recovery. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as "expects", or "does not expect", "is expected", "anticipates" or "does not anticipate", "plans", "budget", "scheduled", "forecasts", "estimates", "believes" or "intends" or variations of such words and phrases or stating that certain actions, events or results "may" or "could", "would", "might" or "will" be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements.Forward-looking statements are subject to a variety of risks and uncertainties which could cause actual events or results to differ from those reflected in the forward-looking statements, including, without limitation: risks related to failure to obtain adequate funding on a timely basis and on acceptable terms; risks related to the outcome of legal proceedings; political and regulatory risks associated with mining and exploration; risks related to the maintenance of stock exchange listings; risks related to environmental regulation and liability; the potential for delays in exploration or development activities or the completion of feasibility studies; the uncertainty of profitability; risks and uncertainties relating to the interpretation of drill results, the geology, grade and continuity of mineral deposits; risks related to the inherent uncertainty of production and cost estimates and the potential for unexpected costs and expenses; results of prefeasibility and feasibility studies, and the possibility that future exploration, development or mining results will not be consistent with the Company's expectations; risks related to the gold price and other commodity price fluctuations; and other risks and uncertainties related to the Company's prospects, properties and business detailed elsewhere in the Company's disclosure record. Should one or more of these risks and uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described in forward-looking statements. Investors are cautioned against attributing undue certainty or reliance on forward-looking statements. These forward-looking statements are made as of the date hereof and the Company does not assume any obligation to update or revise any forward-looking statements, other than as required by applicable law, to reflect new information, events or circumstances, or changes in management's estimates, projections or opinions. Actual events or results could differ materially from those anticipated in the forward-looking statements or from the Company's expectations or projections.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/272690 Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Oct 31, 2025 - (ACN Newswire via SeaPRwire.com) – HighTide Therapeutics, Inc. (2511.HK), a biopharmaceutical company specializing in the development of multifunctional, multi-targeted therapies for chronic metabolic diseases, announced positive 52-week safety and efficacy results from the open-label extension (OLE) phases of two Phase III trials (SYMPHONY-1 and SYMPHONY-2) evaluating HTD1801 in patients with type 2 diabetes mellitus (T2DM).The 52-week data from these two Phase III clinical trials demonstrate the durability of response and highlight the comprehensive long-term clinical benefits of HTD1801 in patients with T2DM. HighTide plans to submit a new drug application (NDA) for HTD1801 as a treatment for T2DM to the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) later this year.SYMPHONY-1 (NCT06350890) and SYMPHONY-2 (NCT06353347) are randomized, double-blind, placebo-controlled, Phase III clinical trials designed to evaluate the efficacy and safety of HTD1801 in adults with T2DM and inadequate glycemic control despite diet and exercise (SYMPHONY-1; N=408) or with Metformin (SYMPHONY-2; N=551). The primary endpoint in both studies was the change in glycated hemoglobin (HbA1c) from baseline with HTD1801 compared to placebo after 24 weeks of treatment. Patients were eligible to continue in a 28-week OLE during which all patients received HTD1801; Durability of response across efficacy endpoints was evaluated based on the change from baseline to Week 52.Efficacy observed during the 24-week double-blind period was durable and maintained with longer-term treatment through 52 weeks in both studiesSYMPHONY-1 (HTD1801 as monotherapy): At week 24, the reduction from baseline in HbA1c with HTD1801 (-1.3%) was superior to placebo. HbA1c reductions were maintained in patients who continued receiving HTD1801 (-1.2% at Week 52). Placebo patients who switched to HTD1801 saw a reduction in HbA1c of -1.3% at Week 52, substantiating the double-blind phase findings.SYMPHONY-2 (HTD1801 as an add-on therapy to Metformin): At week 24, the reduction from baseline in HbA1c with HTD1801 (-1.2%) was superior to placebo. HbA1c reductions were sustained in patients who continued receiving HTD1801 (-1.1% at Week 52). Placebo patients who switched to HTD1801 saw a reduction in HbA1c of -1.2% at Week 52, also substantiating the double-blind phase findings.In both studies, the durability of effect on other cardiometabolic and renal endpoints was maintained at 52 weeks, suggesting comprehensive advantages of HTD1801 beyond glycemic control with long-term treatment.In both studies, the proportion of patients receiving HTD1801 during the double-blind phase who achieved target HbA1c

NEW YORK, Oct 31, 2025 - (ACN Newswire via SeaPRwire.com) - TruMerit President and CEO Peter Preziosi has been elected President of the Conference of Non-Governmental Organizations in Consultative Relationship with the United Nations, also known as CoNGO.CoNGO | TruMeritConference of Non-Governmental Organizations in Consultative Relationship with the United Nations, also known as CoNGO and TruMeritCoNGO is an international non-governmental organization founded in 1948 that relates to the United Nations through its General Consultative Status granted by the United Nations Economic and Social Council (ECOSOC). It has 525 member organizations from around the world and 106 associate members.Dr. Preziosi was elected to serve for the 2025-29 term this week at the 28th CoNGO General Assembly, which took place in New York with the virtual participation of organizations from around the world. He succeeds the Rev. Dr. Liberato C. Bautista, the main representative to the UN for the General Board of Church and Society of The United Methodist Church, who has served as CoNGO's President since 2017 and also held the post from 2007 to 2011.TruMerit has been a member of CoNGO since 2018 and is active in the organization's affairs, having served as the organization's Secretary to the CoNGO Board and as chair of its Membership Committee.Dr. Preziosi is the first Registered Nurse to serve as CoNGO President. He is a nonprofit executive who since early 2023 has led TruMerit, formerly known as CGFNS International, a health workforce development organization committed to advancing the ethical mobility and professional growth of health workers worldwide. Previously, he was employed by the World Health Organization to help establish its technology-driven global learning center, the WHO Academy.Dr. Bautista, the former President of CoNGO, extended his warm congratulations to Dr. Preziosi on his election. "His experience at TruMerit and at WHO, coupled with his profound dedication to multilateralism and his engagement with civil society, provide a basis for optimism regarding CoNGO's future. In an era where the voice and influence of civil society are of paramount importance in shaping a shared future that upholds human dignity and rights, as well as planetary sustainability, Dr. Preziosi's leadership is expected to enhance CoNGO's role as a pivotal supporter and advocate for democratic and equitable participation within the United Nations and beyond," he stated."CoNGO has long been a vital convener of NGOs, a bridge between civil society and an advocate for their engagement at the United Nations, as well as a steadfast champion of inclusive multilateralism - a concept that, unfortunately, is increasingly under attack," said Preziosi."In response, let us assert civil society participation at the United Nations not as a plea, but as a principle - one that is essential to legitimate, effective, and ethical multilateralism, and thereby is critical to the attainment of the Sustainable Development Goals and adherence to the rule of law," he said.About CoNGO (Conference of Non-Governmental Organizations in Consultative Relationship with the United Nations)The Conference of Non-Governmental Organizations in Consultative Relationship with the United Nations (CoNGO) is an independent, international membership association founded in 1948, the year of the Universal Declaration of Human Rights. As a non-governmental organization (NGO) in general consultative status with the UN Economic and Social Council, our work relates to the entire United Nations System: the Secretariat, Agencies, Treaty Bodies, Regional Commissions, Institutes, Summits and World Conferences.CoNGO wholeheartedly endorses the goals and values enshrined in the United Nations Charter and is a strong advocate for multilateralism to resolve global political, environmental, health, and other threats. Close to 30 CoNGO Substantive Committees (called NGO Committees) related to CoNGO in New York, Geneva, Vienna, and regions worldwide demonstrate our commitment to supporting the mission of the United Nations, systemwide. CoNGO has a membership of diverse NGOs working in consultation with the United Nations, in collaboration with each other, and in cooperation with other like-minded stakeholders. ngocongo.orgAbout TruMeritTruMerit is a worldwide leader in healthcare workforce development. Formerly known as CGFNS International, the organization has a nearly 50-year history supporting the career mobility of nurses and other healthcare workers - and those who license and hire them - by validating their education, skills, and experience as they seek authorization to practice in the United States and other countries. As TruMerit, this mission has been expanded to building workforce capacity that meets the needs of people in a rapidly evolving global health landscape. Through its Global Health Workforce Development Institute, the organization is advancing evidence-based research, thought leadership, and advocacy in support of healthcare workforce development solutions, including globally recognized practice standards and certifications that will enhance career pathways for healthcare workers. www.trumerit.orgContact InformationDavid St. Johndstjohn@trumerit.orgSOURCE: TruMerit Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Auckland, New Zealand, Oct 30, 2025 - (ACN Newswire via SeaPRwire.com) - At the inaugural European Union – New Zealand Business Summit, Decent Cybersecurity represented Europe's growing strength in digital and defence technologies. The company's Founder and CEO, Matej Michalko, joined industry leaders to discuss innovation partnerships, cybersecurity resilience, and post-quantum readiness across trans-Pacific markets. The event gathered over 400 participants from business, technology, and research communities, underscoring a shared commitment to building secure and sustainable digital infrastructure between Europe and New Zealand.Hosted by Hon Todd McClay, New Zealand's Minister for Trade & Investment, in partnership with Team Europe (the Ambassadors of the EU and its Member States), the Summit celebrated the strong growth of trans-Pacific cooperation. Since the EU–NZ Free Trade Agreement entered into force in 2024, two-way trade has already risen by NZ $2 billion, reaching NZ $21.6 billion in 2025.The event was officially opened by Prime Minister Christopher Luxon, who described the EU as "an innovation partner" and emphasised the shared values and strategic alignment between Europe and New Zealand in advancing trade, defence, and technology.A Platform for Global Partnerships and Digital InnovationCommissioner Šefcovic, a native of Slovakia, delivered a keynote address outlining Europe's vision for resilient supply chains, strategic autonomy, and secure digital transition. Later in the day, the "Quickfire with Central and Eastern Europe" session showcased innovation leaders from across the region.Representing European Union and its member country Slovakia, Matej Michalko presented on the country's growing role in post-quantum cybersecurity, AI for defence systems, and trusted blockchain infrastructure — areas where Decent Cybersecurity is establishing Europe-wide leadership."It was an honour to represent European Union and Slovakia alongside Commissioner Šefcovic and to demonstrate how our country is contributing to Europe's digital and defence sovereignty," said Matej Michalko, CEO of Decent Cybersecurity. "The EU–New Zealand partnership opens new doors for innovation, technology exchange, and secure infrastructure development that transcend continents."Shared Vision for Innovation and SecurityThe Summit agenda featured strategic panels on clean tech, AI, bioeconomy, and aerospace & defence, with global leaders from Airbus, Rocket Lab, OHB, and Maersk. It culminated with a joint address by Commissioner Šefcovic and Minister McClay, setting out a shared vision for deeper economic and technological integration between Europe and New Zealand — an effort strongly endorsed by Prime Minister Luxon in his opening remarks.For Decent Cybersecurity, participation in this summit reinforces its mission to connect European post-quantum, blockchain and AI-driven innovation with global partners in the Asia-Pacific region — bridging defence, technology, and critical-infrastructure ecosystems.About Decent CybersecurityDecent Cybersecurity s. r. o. is a European deep-tech company developing post-quantum and blockchain-based cybersecurity solutions for defence and critical infrastructure. Certified by TÜV SÜD (ISO 9001 and ISO 27001) and holding NATO, EU, and national SECRET-level security clearances, the company is a member of European Defence Fund (EDF) projects and a founding member of the Critical Infrastructure Association of Slovak Republic (Asociácia kritickej infraštruktúry SR, AKI SR).Media contactBrand: Decent CybersecurityContact: Media teamWebsite: https://decentcybersecurity.eu Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

SHENZHEN, Oct 30, 2025 - (ACN Newswire via SeaPRwire.com) - China Medical System Holdings Limited (“CMS”) is pleased to announce that its subsidiary, Dermavon Holdings Limited (“Dermavon”, an innovative pharmaceutical company specialized in skin health which is applying for a separate listing on the Main Board of The Stock Exchange of Hong Kong Limited, please refer to the announcement of CMS on 22 April 2025 for details) together with its subsidiaries, holds co-development rights (except for atopic dermatitis (AD)) and exclusive commercialization rights for the Class 1 innovative drug anti-IL-4Rα MG-K10 humanized monoclonal antibody injection (“MG-K10” or the “Product”). The New Drug Application (“NDA”) has been accepted by National Medical Products Administration (“NMPA”) on 30 October 2025. The product is intended for the treatment of adult with moderate-to-severe AD whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.MG-K10 (generic name: Comekibart Injection) is an innovative long-acting anti-IL-4Rα humanized monoclonal antibody that simultaneously blocks the signaling of key type 2 inflammatory cytokines IL-4 and IL-13. With a longer half-life, the Product enables a four-week dosing frequency (currently marketed anti-IL-4Rα drugs require biweekly dosing), which is expected to improve patient adherence. MG-K10 is expected to become the world's first long-acting anti-IL-4Rα monoclonal antibody to be launched on the market, and has the potential to become the Best-in-Class (BIC).MG-K10 has achieved positive results in a randomized, double-blind, placebo-controlled Phase III clinical study in adults with moderate-to-severe AD, meeting the primary research endpoint as designed, and at 52 weeks of treatment with MG-K10, proportion of participants with Investigator Global Assessment (IGA) score of 0 or 1, also with an improvement of ≥2 points from baseline is 76.6%; proportion of participants with ≥75% reduction in Eczema Area and Severity Index (EASI 75) from baseline is 94.3 %; proportion of participants with ≥90% reduction in Eczema Area and Severity Index (EASI 90) from baseline is 79.1 %. Regarding safety, most of the Treatment Emergent Adverse Event (TEAE) were Grade 1-2, with no Adverse Event of Special Interest (AESI) or fatal adverse event occurred. The incidence of common adverse reactions (conjunctivitis, injection site reactions, etc.) of drugs with the same target is relatively low for MG-K10.The Product has the potential for the treatment of other type 2 inflammatory diseases, such as asthma, prurigo nodularis, seasonal allergic rhinitis, chronic obstructive pulmonary disease, chronic spontaneous urticaria, chronic rhinosinusitis with nasal polyps, and eosinophilic esophagitis. Among them, asthma, prurigo nodularis and seasonal allergic rhinitis have all entered the phase III clinical trial stage in China.If MG-K10 is approved, it will provide a new, effective, and safe systemic treatment option for 14.5 million patients with moderate-to-severe AD[1]. Furthermore, MG-K10 will generate synergy with Dermavon's ruxolitinib cream (for mild to moderate AD), the oral small molecule TYK2 inhibitor CMS-D001 (for moderate to severe AD), and dermatology-grade skincare products of Heling soothing product series, establishing a comprehensive solution for AD that covers various administration routes (injection, oral, and topical) and addresses multiple needs in “treatment + care”, benefiting a wide range of AD patients. Concurrently, it will further enrich Dermavon's product portfolio in the field of dermatological treatment and reinforce its leading position in skin health sector.On 24 January 2025, CMS through its subsidiaries entered into a Collaboration Agreement (“Agreement”) with Hunan Mabgeek Biotech Co., LTD and its subsidiaries for MG-K10. In accordance with the Agreement and supplementary agreements, CMS has obtained the co-development rights (excluding AD) and exclusive commercialization rights for the Product in Mainland China, Hong Kong Special Administrative Region, Macao Special Administrative Region, Taiwan Region and Singapore; its subsidiary Dermavon has obtained, through its subsidiary, the co-development rights (excluding AD) and exclusive commercialization rights for the Product in the field of dermatological indications in Mainland China.About AD IndicationMG-K10’s first indication, AD, is a chronic inflammatory skin disease accompanied by severe itching. It is the most burdensome non-fatal skin disease worldwide and also a chronic disease with a relatively high prevalence and significant disease burden in China. It is estimated that there are over 54 million AD patients in China in 2024. Based on SCORAD scores, the proportion of moderate to severe AD in China was 27%, which means there are over 14.5 million patients[1]. Due to the limitations in efficacy and safety of traditional systemic therapies for AD, moderate to severe AD patients often experience delays in systemic treatment initiation, poor compliance, and suboptimal disease control, leaving a significant unmet need in clinical practice[2]. MG-K10, with its extended dosing interval of once every four weeks, is expected to improve patient adherence and provide a new, effective, and safe systemic treatment option for patients with moderate-to-severe AD.About CMSCMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the cardio-cerebrovascular/ gastroenterology/ ophthalmology/ skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development of the Group.Reference:1. China Insights Consultancy. Industry report on global and China Dermatology Treatment and Care Industry2. Chinese Society of Dermatology, China Dermatologist Association. Clinical pathway for the diagnosis and treatment of moderate to severe atopic dermatitis in China (2023): an expert consensus[J]. Chinese Journal of Dermatology, 2023, 56(11): 1000-1007. DOI: 10.35541/cjd.20230247.CMS Disclaimer and Forward-Looking StatementsThis press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.Media ContactBrand: China Medical System Holdings Ltd.Contact: CMS Investor RelationsEmail: ir@cms.net.cnWebsite: https://web.cms.net.cn/en/home/ Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Oct 30, 2025 - (ACN Newswire via SeaPRwire.com) – Esperanza Fintech (Hong Kong) Limited (“Esperanza” or the “Group”) today hosted the “Conference: Implementation of Tokenized Economy by Esperanza” (“Conference”). It is an opportune moment as the Hong Kong SAR Government vows in her 2025 Policy Address to support the development of tokenized gold investment products. The Conference brought together industry leaders and partners to map out a strategic blueprint to implement tokenized economy, including the compliant roadmap for tokenized gold in Hong Kong and the unlimited potential of tokenized investments, an application for tokenized gold, in driving economic growth in the Asia-Pacific region. The Conference was attended by nearly a hundred investors and professionals.The Conference kicked off with a vision speech delivered by Mr. Ronald Leung, solicitor, Founder and Group CEO of Esperanza. Mr. Leung pointed out that the Asia-Pacific region has long relied on Western settlement systems and Western-dominated interest rate policies. The tokenized economy, powered by tokenized gold, offers an alternative capital solution to drive regional economic development and the continuous internationalization of the financial and capital markets of the Chinese Mainland and Hong Kong . He emphasized that the support for development of tokenized gold in Hong Kong’s 2025 Policy Address is a highly strategic policy direction. Capitalizing on her status and resources as an international financial center, Hong Kong possesses unparalleled edge in developing an ecosystem powered by tokenized gold in facilitating cross-border trades in the Asia-Pacific region. Furthermore, tokenized gold could be integrated with Central Bank-led digital Renminbi (RMB) in the future to contribute to the internationalization of RMB. He pointed out that the Group has completed registration with the Hong Kong Customs as an issuer of precious asset-backed instrument. The Group has also undergone a small-scale, non-public proof-of-concept (POC) testing in multiple Asia Pacific markets, including Southeast Asia, Australia, Japan, South Korea, and currently has significant verified “Know Your Customer (KYC)” POC users. Although Esperanza's tokenized gold is designed based on the legal framework for precious asset-backed instrument registered with Hong Kong Customs, to ensure overall regulatory stability in Hong Kong, it is anticipated that Esperanza will open its tokenized gold offerings to the Hong Kong public only after addressing the concerns of other regulatory bodies and when a clear regulatory framework is fully implemented in the city. The Group will also align with governments of various economies on operational fronts via strategic partners.Mr. Leung continued to point out, "Tokenized gold is a key milestone for Hong Kong's financial future. Esperanza has already signed an agreement with Hatcher Group Limited (8365.HK) regarding the development of tokenized gold before the Policy Address was released. Immediately following the release, our team has conducted a productive and in-depth communication with the Chief Executive's Policy Unit, while ensuring our technology platform and infrastructure are in place and ready for action. Currently, we are maintaining active dialogues with regulators, with the core principle of achieving ‘controllable innovation’ that adheres to existing regulatory framework as well as the work agenda of the Chief Executive’s Policy Unit. We firmly believe that Esperanza, armed with first-mover advantages in technology and its business model, and in collaboration with various sectors, will be able to transform tokenized gold into a powerful engine in driving economic autonomy in the Asia-Pacific region."The conference had two thematic sharing sessions. The first had Mr. Roy Lui, Managing Director of ESPE Gold Solutions, sharing the compliant implementation of tokenized gold in Hong Kong. Mr. Lui shared that the Group’s proposed solution – “ESPE Gold” (“ESPG”) – is legally categorized as a “precious asset-backed instrument” instead of a virtual asset or a stablecoin, nor a collective investment scheme. Esperanza purchases physical gold bars adhering to London Bullion Market Association (LBMA) standards, stores them in licensed gold vaults and issues 100,000 ESPG, i.e. digital gold certificates, for each kilogram of gold bar. These digital gold certificates, each representing a complete instalment payment, are recorded on blockchain networks. Upon completion of 100,000 instalments, i.e. holding 100,000 ESPG, clients can redeem physical gold bars from Esperanza. Clients can make instalment payments any time and sell ESPG back to Esperanza, enjoying much higher flexibility than traditional gold redemption clubs. Mr. Lui emphasized that, although ESPG gives users experiences similar to that of stablecoins, the business model is actually more akin to traditional gold dealers earning bid-ask spread. He also spoke on the diverse application scenarios of ESPG besides as a convenient way to purchase physical gold. ESPG is poised to develop into a cross-border settlement means for commerce across Asia economies, with future potential to power a gold-backed interest rate system through collateralized lending of ESPG.In the second sharing session, Mr. Tony Chang, Executive Director of ESPE Capital Solutions, talked about the Group’s blueprint for tokenized investments as a core use case for tokenized gold. Mr. Chang said tokenized investments have not seen significant breakthrough due to the lack of product designs that are attractive to investors and that liquidity is highly concentrated within professional investors. Tokenized investments need to deliver both “attractive growth potential” and “security in exit channels” in order for investors to make meaningful consideration for adoption. Such example includes a short-term revenue sharing arrangement with foreseeable potential for revenue improvement. He added that Esperanza has obtained the Asset Management licence from the Securities and Futures Commission (SFC) of Hong Kong and its application for tokenized business is currently under review, with the legal, tax, and trading infrastructures ready. Currently, the Group’s tokenized investment pipelines include concert revenue of Southeast Asian and Korean artists, movie box office receipts and revenue of hotels and shopping malls.In addition to the thematic sharing sessions, the conference also featured a panel discussion comprising Mr. Jeremy Teo from Singapore, Co-founder and Board Director of Esperanza, Mr. Ronald Leung and Mr. Tony Chang. The discussion centers on the development potential of tokenized gold and tokenized investments across various Asia-Pacific economies, particularly the opportunities in bringing Southeast Asian projects to Hong Kong for capital raising via security token offerings (STOs). These opportunities illustrate the advantages for Hong Kong in developing tokenized gold with the support of the Hong Kong SAR Government.The conference marked an important step made by Esperanza in promoting the development of tokenized economy in Hong Kong and across Asia. Looking ahead, the Group will continue to provide innovative fintech solutions to support Hong Kong in strengthening her position as an international financial center, as well as helping foster greater economic autonomy and financial innovation in the Asia-Pacific region.Photo captionsPhoto 1: (From left to right) Mr. Tony Chang, Executive Director of ESPE Capital Solutions, and Mr. Ronald Leung, Founder and Group CEO of Esperanza, and Mr. Roy Lui, Managing Director of ESPE Gold Solutions, at the conference.Photo 2: (From left to right) Mr. Jeremy Teo, Co-founder and Board Director of Esperanza, Mr. Ronald Leung, Founder and Group CEO of Esperanza, and Mr. Tony Chang, Executive Director of ESPE Capital Solutions, after the panel discussion session.About Esperanza Fintech (Hong Kong) Limited (Esperanza)Esperanza is co-founded by the next generation of professionals from Hong Kong and Singapore with the mission to reform Asia’s economies through fintech. Esperanza is building the world’s first digital economy powered by a compliant tokenized gold infrastructure and its applications in finance. Esperanza aspires to reconnect Asia’s economies and integrate with their respective Central Bank Digital Currencies (CBDCs) to build autonomy against reliance on Western settlement systems and interest rate policies.Esperanza operates on a low-profile, highly efficient, and decisive business model. Since commencement in 2025, Esperanza has secured the registration as a Precious Metals and Stones Dealer (DPMS) with Hong Kong Customers and the Trust or Company Service Provider (TCSP) licence for the operations and custody of tokenized gold, and the Asset Management licence with the Securities and Futures Commission (SFC) of Hong Kong for the development of tokenized investments.In August 2025, Esperanza entered into a partnership agreement with Hatcher Group (8365.HK) relating to tokenized gold and tokenized investments. In September 2025, Hong Kong government has included the development of tokenized gold into its 2025 Policy Address.Esperanza's tokenized gold and tokenized investments continue to adhere to Hong Kong's Anti-Money Laundering (AML) requirements and common reporting standard for counter-tax evasion measures. Fintech solutions have enabled Esperanza to significantly reduce financing and operational costs, connecting products directly with end users. Esperanza’s tokenized finance system will fully support the globalization of national economy and is committed to becoming an alternative solution for international trades and settlements.To find out more, please visit the Esperanza website: espetopia.com Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Oct 30, 2025 - (ACN Newswire via SeaPRwire.com) – Everest Medicines (HKEX:1952.HK) today announced that it has acquired an exclusive license with Visara, Inc. (“Visara”), a subsidiary of NovaBridge Biosciences (formally known as I-Mab, and is a company listed on the Nasdaq Global Market trading under the symbol “NBP”), to secure an exclusive license to develop, manufacture and commercialize VIS-101, in Greater China, Singapore, South Korea and certain Southeast Asian countries.This collaboration marks Everest’s strategic expansion into ophthalmology, a high-potential “blue-ocean” therapeutic area, further enriching its late-stage product pipeline and strengthening synergies across its core therapeutic portfolio.Under the assigned exclusive license, Everest Medicines will make an upfront payment of US$7 million (equivalent to approximately RMB49.7 million) and reimburse up to RMB24.0 million for prior expenses; and pay up to US$89.0 million (equivalent to approximately RMB632.0 million) in potential milestones; plus tied royalties on net sales.“We are pleased to collaborate with Visara. This partnership brings a highly differentiated and commercially attractive asset to Everest’s late-stage product pipeline and marks our entry into ophthalmology, a competitively attractive therapeutic area with significant unmet medical needs,” said Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines. “Leveraging Everest’s clinical development and commercialization expertise, we look forward to advancing VIS-101, a potential best-in-class bifunctional antibody, towards commercialization in China and across Asia.”VIS-101 is a novel bifunctional biologic targeting VEGF-A and ANG-2 that is more potent and could potentially provide more durable treatment benefits than existing treatments for patients with wet age-related macular degeneration, diabetic macular edema, and retinal vein occlusion. VIS-101 has completed initial safety and dose-escalation studies in both the United State of America and China, and is currently completing a randomized, dose-ranging Phase 2 study in China. VIS-101 is anticipated to be Phase 3-ready in 2026.“VIS-101 is anticipated to be second-in-class with best-in-class potential, based on bioengineered, superior target neutralizing capabilities.” said Dr. Emmett T. Cunningham, Jr, Co-Founder and Executive Chairman of Visara.Globally, the market size for anti-VEGF ophthalmic drugs reached approximately USD 23 billion in 2024 and is projected to exceed USD 40 billion by 2030. In China alone, the prevalent patient population of AMD and DME exceeds 15 million, with around 600,000 new cases each year, yet only about 500,000 patients currently receive treatment. This indicates vast market potential.Visara is a subsidiary of NovaBridge Biosciences (Nasdaq: NBP), of which Everest Medicines is currently the largest shareholder. “Licensing out Greater China, South Korea and Southeast Asia rights to Everest Medicines is an important step toward streamlining global commercial rights and creating synergy in global clinical development,” said Dr. Sean Fu, Chief Executive Officer of NovaBridge Biosciences. “We are excited to work with Everest Medicines team as a strategic partner."Under its “dual-engine” strategy, Everest Medicines has established a commercialization platform anchored by two blockbuster products targeting high-potential markets and powered by the in-house in vivo CAR-T and mRNA therapeutic cancer vaccine platforms. The Company will continue to focus on key therapeutic areas and new growth markets, with ophthalmology as the next growth driver to strengthen synergy across its core portfolio.Everest’s core product pipeline in rental diseases, infectious diseases, and autoimmune disorders has entered a critical growth stage. NEFECON® and XERAVA® have established sustainable commercial cash flow generation, while VELSIPITY® (etrasimod) is expected to become the company’s next blockbuster product. Everest continues to enhance its innovation capability and long-term competitiveness by leveraging its industry-leading mRNA therapeutic cancer vaccine platform and mRNA in vivo CAR-T platform.At a recent corporate strategy meeting, Everest Medicines announced plans to in-license more than three high-potential assets within the next 6–12 months, with an aggregate domestic peak sales potential exceeding RMB10 billion. Combined with its existing portfolio, Everest Medicines expects its total domestic peak sales potential to surpass RMB20 billion. Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com